Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: a case series
File(s)AJH-21-1019.R1_Proof_hi.pdf (436.21 KB)
Accepted version
Author(s)
Type
Journal Article
Date Issued
2021-12-01
Date Acceptance
2021-09-27
Citation
American Journal of Hematology, 2021, 96 (12), pp.E461-E463
ISSN
0361-8609
Publisher
Wiley
Start Page
E461
End Page
E463
Journal / Book Title
American Journal of Hematology
Volume
96
Issue
12
Copyright Statement
© 2021 Wiley Periodicals LLC. This is the accepted version of the following article: Biliński, J., Jasiński, M., Tomaszewska, A., Lis, K., Kacprzyk, P., Chmielewska, L., Karakulska-Prystupiuk, E., Mullish, B.H. and Basak, G.W. (2021), Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series., which has been published in final form at https://doi.org/10.1002/ajh.26365
Sponsor
Imperial College Healthcare NHS Trust- BRC Funding
Identifier
https://onlinelibrary.wiley.com/doi/10.1002/ajh.26365
Grant Number
RDA02
Subjects
Science & Technology
Life Sciences & Biomedicine
Hematology
Immunology
1102 Cardiorespiratory Medicine and Haematology
Publication Status
Published
Date Publish Online
2021-09-29